

Spring 5-22-2012

A new successful vaccine against babesiosis: Any use for malaria?

Thep Schetters
Merck

Follow this and additional works at: http://dc.engconfintl.org/vaccine_iv




Part of the [Biomedical Engineering and Bioengineering Commons](#)

Recommended Citation

Thep Schetters, "A new successful vaccine against babesiosis: Any use for malaria?" in "Vaccine Technology IV", B. Buckland, University College London, UK; J. Aunins, Janis Biologics, LLC; P. Alves, ITQB/IBET; K. Jansen, Wyeth Vaccine Research Eds, ECI Symposium Series, (2013). http://dc.engconfintl.org/vaccine_iv/21


This Conference Proceeding is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Vaccine Technology IV by an authorized administrator of ECI Digital Archives. For more information, please contact franco@bepress.com.




VACCINATION AGAINST BABESIA

Implications for malaria ?

BLOCKED CAPILLARIES-BABESIA




Brain section of *B. canis* infected dog




Gut section of *B. canis* infected dog

In clinical babesiosis capillaries become blocked

BLOCKED CAPILLARIES-BABESIA



B. bovis infected red blood cell



B. canis infected red blood cell

Infected red blood cells adhere to the lining of blood vessels (margination), but ridges are not absolutely required

CIRCULATORY DISTURBANCES-BABESIA



Not-infected control dog



- Anaemia
- Prolonged capillary refill time
- Poor tissue perfusion
- Sharp pulse (decreased capillary resistance)



B. canis infected dog




CIRCULATORY DISTURBANCES-BABESIA



Collapsed arterioles in the mucosae of a *B. canis*-infected dog (left). Control on the right. Note absence of filled arterioles in infected dog


COMPENSATED HYPOTENSION-BABESIA




B. canis infected dogs (n=3). Arrow indicates day of cure of 10⁶ group

Dogs develop hypotension upon *B. canis* infection. Non-cured dogs restored blood pressure in two days (blue bar)

COMPENSATED HYPOTENSION-BABESIA




Water balance in *B. canis* infected dogs (n=2)




Body weight increase in *B. canis* infected dogs (n=2)

During the phase of hypotension water is retained, reflected in increased body weight
-dogs were kept in metabolic cages after *B. canis* infection-

COMPENSATED HYPOTENSION-BABESIA



Dynamics of creatinin and red blood cell concentrations in *B. canis* infected dogs (n=5)




Correlation between concentrations of creatinin and red blood cells in *B. canis* infected dogs (n=5)

During hypotension water is retained, reflected in dilution of blood components
-dilution of creatinin is similar to that of the red blood cells-


COMPENSATED HYPOTENSION-MALARIA

Orthostatic hypotension




Due to decreased capillary resistance orthostatic hypotension leads to dizziness and syncope (fainting)

COMPENSATED HYPOTENSION-MALARIA



Plasma volume changes in *P. falciparum* patients receiving therapeutic treatment (n=23). Average change is 485 ml, 12.5% (p<0.001)




Dynamics of red blood cell concentrations in patients receiving therapeutic *P. falciparum* infection

During hypotension water is retained, reflected in dilution of blood components


BLOCKED CAPILLARIES-BABESIA

CONCLUSIONS

- Early in Babesia infection dogs develop **hypotension**
- Hypotension is **compensated** by increase of blood volume in 2-3 days
- Haematocrit decreases are largely the result of **haemodilution**
- **Capillary resistance** remains low which reduces blood flow through capillaries
- Reduced blood flow facilitates **adherence** of infected red blood cells
- Similar processes occur in **malaria**
- These aspects are largely neglected



VACCINATION-BABESIA



Supernatants of in vitro cultures of the parasite can be used as vaccines

VACCINATION-BABESIA

Antigen production (SPA)




Adjuvant production (saponin)




A single dose is supernatant antigen (SPA) produced by 1×10^8 infected erythrocytes. Quil A (250 ug/ml) is used as adjuvant. A single dose volume is 1ml. Two subcutaneous injections with 3-week interval

VACCINATION-BABESIA




Effect of vaccination of dogs with SPA on the red blood cell concentration (PCV) in blood. Data represent the average values from vaccinated and controls dogs (n=5)



Effect of vaccination of dogs with SPA on the creatinin concentration in blood. Data represent the average values from vaccinated and controls dogs (n=5)

Vaccination with SPA controls excessive PCV and creatinin decreases

VACCINATION-BABESIA




Effect of vaccination of dogs with SPA on the red blood cell concentration (PCV) and creatinin concentration in blood. Data represent the difference between values from vaccinated dogs and controls dogs (n=5)




Protected dog

Because both parameters are affected to the same extent it is concluded that vaccination with SPA limits haemodilution

VACCINATION-BABESIA




Dynamics of parasitaemia (squares) and SPA concentrations (crosses) in vaccinated dogs (n=5)



Dynamics of parasitaemia (squares) and SPA concentrations (crosses) in control dogs (n=5)

Not peripheral parasitaemia but the level of SPA in plasma correlates with protection

VACCINATION-BABESIA



The antibody response against SPA correlates with protection


VACCINATION-BABESIA

CONCLUSIONS

- SPA of Babesia canis parasites cause disease
- Vaccination with SPA induces protection
- Protection is reflected in decreased SPA in plasma
- Protection is associated with an **antibody response against SPA**
- In experimental infections anti-SPA response is absent
- Vaccine-induced protection is essentially different from infection-induced protection




ANALYSIS SUPERNATANT ANTIGENS



A doublet at Mr 38-40kDa is produced by *B. canis* after 15 minutes pulse and chased at different time points

ANALYSIS SUPERNATANT ANTIGENS




Vaccination-challenge serum recognizes SPA (mainly Mr 38kDa molecule)
-western blot analysis-

VACCINATION REC. SPA 1 ANTIGEN

DISCOVERY OF THE SPA1 GENE OF BABESIA CANIS

- The major antigens from SPA of B. canis were purified
- Partial amino acid sequences were revealed
- The genome of B. canis was sequenced
- The gene encoding for SPA1 was identified



RECOMBINANT SPA 1 ANTIGEN

SPA1 GENE OF BABESIA CANIS

1 MMLLFALSTL VTEAFCD**GEN** **TILLSNVEFH** TPVSSVKLLK **EYSSNQESMA**
51 **VIMMLTEMPN** **TSGK**LTDGKV **HVANDNVK****C**A DLALAYQELK KAGKVTSWSP
101 TDDNDKVVPH GIWFIEGVYE TDKMFEVYKT **LTD****PEDPSEV** **TRL**TTVSGAS
151 GSAQSQPAGT TDGVSGSAAS ASGSSGSTTS HSTTATTSST STVSTSSSGA
201 STSSSTDQAS MLTTOTSYS A GSSVHK**SAVV** **APTQSTTPDN** **AESGAKQSKA**
251 AVQEPK**NVLM** **ILTK****C**DLK**AE** **VTEEQIRSQG** NPESNGSSSE **PTAASPKLTT**
301 AASGFTAAIT PLEFMVPLMFF A

Signal sequences are boxed (GPI-anchored!)

In **blue**, peptides from purified SPA1b Mr40kDa (technique 1)


In **blue/italics**, peptide from purified SPA1a Mr 38kDa (technique 1)

In **red**, peptides from SPA1b (technique 2)

In **yellow** circles, cysteines that can lead to intramolecular di-sulphide bond

The SPA doublet is encoded by a single gene


RECOMBINANT SPA 1 ANTIGEN



Production of recombinant SPA1 antigen in *E. coli*

SEROCONVERSION RECOMBINANT SPA 1

rSPA1 antibody titers in dogs




Vaccination (day 0, 21 and 42) with Quil A adjuvant. Challenge day 56.

CLINICAL SIGNS

O
V
E
R
T


C
L
I
N
I
C
A
L

D
I
S
E
A
S
E




Vaccinated dogs are protected from clinical disease
-circulatory problems in control dogs from day 11 onwards-

PACKED CELL VOLUME



Vaccinated dogs showed limited decreases in packed cell volume

PARASITAEMIA



Development of parasitaemia is limited in vaccinated dogs


VACCINATION REC. SPA 1 ANTIGEN

CONCLUSIONS -Babesia


- Vaccination of dogs with recombinant SPA1 protects against virulent challenge infection
- Protection is reflected in:
 - Limited decrease in packed cell volume
 - Restricted development of parasitaemia
 - Reduction in clinical signs (circulatory stress)
- It is hypothesized that vaccination interferes with pathological processes that lead to parasite localization which favours parasite proliferation (chronic infection)
- Similar pathological processes have been described in malaria and other systemic diseases



VACCINATION-MALARIA



The vaccine principle was claimed to work in the *P. falciparum*-squirrel monkey model....



...but the principal investigator was discredited and the research line was abrogated

ACKNOWLEDGEMENTS

Jos Kleuskens, Nicolette Scholtes, Jos van de Crommert, Elle Krijnen, Karin Kuiper, Leonie Janssen, Liselotte Wolters, Ruud Segers, Mieke Vrijenhoek, Eric van Esch, Karel van Stokkom, Walter Barendts, Evelien van Kempen, Marianne Smit, Danny Goovaerts, Jan Pasma, Gerard de Snayer, Emiel Hendriks, Dominique Clercx, Andre Gorenflot, Eric Precigout, Bernard Carcy, Karina Moubri, Stephane Delbecq, Tom Strydom, Neil Fourie, Tshepo Matjila, Banie Penzhorn, Brian Cooke, David Allred, Bernadette Scholts, and all those who contributed but are not listed here